$63.00
Manufacturer: Poland
Purpose: Blocks estrogen receptors in the urinary tract, treating lower urinary tract symptoms.
Description
Feminost Uro tablets №56
Ingredients
Feminost Uro tablets №56 contain a unique blend of cranberry extract, D-mannose, and probiotics that work synergistically to support urinary tract health.
Dosage
Recommended dosage: Take 1 tablet twice daily with water. Do not exceed the recommended dose.
Indications
These tablets are indicated for individuals looking to maintain a healthy urinary tract and prevent recurrent urinary tract infections.
Contraindications
Do not use if you are allergic to any of the ingredients. Consult your healthcare provider before use if you are pregnant, nursing, or taking other medications.
Directions
For best results, take Feminost Uro tablets №56 consistently as directed. Drink plenty of water throughout the day to support urinary health.
Scientific Evidence
Studies have shown that cranberry extract and D-mannose can help prevent the adhesion of bacteria to the urinary tract, reducing the risk of infections. Probiotics in the formulation promote a healthy balance of gut flora, which may indirectly benefit urinary tract health.
Additional Information
In addition to supporting urinary tract health, Feminost Uro tablets №56 may also help maintain a healthy digestive system due to the presence of probiotics. Regular use of these tablets can contribute to overall well-being.
Pharmacological effects of Feminost Uro tablets №56 involve the inhibition of bacterial adhesion to the urinary tract epithelium, thereby reducing the likelihood of urinary tract infections. The cranberry extract and D-mannose components interfere with the attachment of bacteria to the bladder wall, promoting their excretion through urine.
Clinical trials have demonstrated the efficacy of cranberry extract and D-mannose in preventing recurrent urinary tract infections. A study published in the Journal of Clinical Microbiology found that the combination of cranberry and D-mannose significantly reduced the incidence of UTIs compared to a placebo group.
Recent Reviews